Acknowledgement
This research was supported by the Kyungpook National University Research Fund (2020).
References
- Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019;139:e56-528.
- Lee SE, Lee HY, Cho HJ, Choe WS, Kim H, Choi JO, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure Registry (KorAHF). Korean Circ J 2017;47:341-53. https://doi.org/10.4070/kcj.2016.0419
- Ahn MS, Yoo BS, Yoon J, Lee SH, Kim JY, Ahn SG, et al. Prognostic effect of guideline-directed therapy is more noticeable early in the course of heart failure. J Korean Med Sci 2019;34:e133. https://doi.org/10.3346/jkms.2019.34.e133
- Kim MS, Lee JH, Kim EJ, Park DG, Park SJ, Park JJ, et al. Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J 2017;47:555-643. https://doi.org/10.4070/kcj.2017.0009
- Lee JH, Kim MS, Yoo BS, Park SJ, Park JJ, Shin MS, et al. KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of acute heart failure. Korean Circ J 2019;49:22-45. https://doi.org/10.4070/kcj.2018.0349
- Lee JH, Kim MS, Kim EJ, Park DG, Cho HJ, Yoo BS, et al. KSHF Guidelines for the Management of Acute Heart Failure: Part I. Definition, epidemiology and diagnosis of acute heart failure. Korean Circ J 2019;49:1-21. https://doi.org/10.4070/kcj.2018.0373
- Cryer PE, Wortsman J, Shah SD, Nowak RM, Deftos LJ. Plasma chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol 1991;260(2 Pt 1):E243-6.
- Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C, et al. Chromogranins: new sensitive markers for neuroendocrine tumors. Acta Oncol 1989;28:325-9. https://doi.org/10.3109/02841868909111201
- Jansson AM, Rosjo H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009;30:25-32. https://doi.org/10.1093/eurheartj/ehn513
- Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002;23:967-74. https://doi.org/10.1053/euhj.2001.2977
- Ottesen AH, Carlson CR, Louch WE, Dahl MB, Sandbu RA, Johansen RF, et al. Glycosylated chromogranin A in heart failure: implications for processing and cardiomyocyte calcium homeostasis. Circ Heart Fail 2017;10:e003675. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003675
- Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 2006;152:927.
- Rosjo H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, et al. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur J Heart Fail 2010;12:549-56. https://doi.org/10.1093/eurjhf/hfq055
- Kantar M, Levent E, Cetingul N, Ulger Z, Ozyurek R, Aksoylar S, et al. Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity. Pediatr Hematol Oncol 2008;25:723-33. https://doi.org/10.1080/08880010802435393
- Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug: partners in the diagnosis of congestive heart failure. Congest Heart Fail 2004;10(1 Suppl 1):3-27. https://doi.org/10.1111/j.1527-5299.2004.03310.x
- Huang B, Shen J, Li L, Huang Y, Luo S. Effect of B-type natriuretic peptide level on long-term outcome in patients with end-stage heart failure. Am J Cardiol 2016;118:383-8. https://doi.org/10.1016/j.amjcard.2016.05.018
- Kim MS, Lee JH, Cho HJ, Cho JY, Choi JO, Hwang KK, et al. KSHF Guidelines for the Management of Acute Heart Failure: Part III. Specific management of acute heart failure according to the etiology and co-morbidity. Korean Circ J 2019;49:46-68. https://doi.org/10.4070/kcj.2018.0351